annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
Brd. 14B Timing of failure of resected rectal cancer: What is the appropriate duration
of postoperative imaging? (Abstract #3633)
K. Fischkoff, J. Juan, L. Saltz, E. Riedel, M. R. Weiser, G. Nash, L. K. Temple,
P. Paty, W. D. Wong, J. G. Guillem
Brd. 14C Preoperative chemoradiotherapy (QRTP) and total mesorectal excision (TME)
by laparoscopy (LPS) in rectal cancer (RC): Long-term outcomes. (Abstract
#3634)
E. Pineda, X. Garcia-Albeniz, S. Delgado, C. Conill, A. Gines, J. Ayuso, R. Gallego,
M. Cuatrecasas, A. Lacy, J. Maurel
Brd. 14D A randomized phase II trial of preoperative chemoradiotherapy with or
without cetuximab in locally advanced adenocarcinoma of the rectum.
(Abstract #3635)
A. D. McCollum, D. M. Kocs, P. Chada, D. A. Richards, Y. Wang, K. A. Boehm,
L. Asmar, L. Munoz
Brd. 14E Preoperative chemoradiation (CRT) with concurrent capecitabine and
irinotecan in MRI-defined locally advanced rectal cancer: Relationship of
histologic downstaging to long-term survival end points. (Abstract #3636)
S. W. Gollins, S. Myint, S. Susnerwala, M. Wise, B. J. Haylock, M. P. Saunders,
R. Neupane, C. Topham, L. M. Samuel, E. L. Levine
Brd. 14F Chemotherapy induction followed by preoperative chemoradiation versus
preoperative chemoradiation alone in locally advanced rectal cancer (LARC):
A randomized controlled phase II study. (Abstract #3637)
R. Maréchal, B. Vos, M. Polus, T. Delaunoit, M. Peeters, P. Demetter,
P. Van Houtte, A. Demols, J. Van de Stadt, J. Van Laethem
Brd. 14G Short-course radiation therapy, neoadjuvant bevacizumab, capecitabine and
oxaliplatin, and radical resection of primary tumor and metastases in primary
stage IV rectal cancer: A phase II multicenter study of the Dutch Colorectal
Cancer Group. (Abstract #3638)
T. H. van Dijk, K. Havenga, J. Beukema, G. L. Beets, H. Gelderblom,
K. P. de Jong, H. J. Rutten, C. J. Van De Velde, T. Wiggers, G. Hospers
Brd. 14H Effect of preoperative radiotherapy on local recurrences in rectal cancer
patients with PIK3CA mutation. (Abstract #3639)
Y. He, L. van ’t Veer, M. Lopez Yurda, I. Mikolajewska-Hanclich, I. D. Nagtegaal,
C. J. Van De Velde, C. A. Marijnen
Brd. 15A Association of intratumoral gene expression levels of thymidine
phosphorylase (TP) and VEGF with clinical outcome in stage II/III rectal
cancer patients treated with 5-fluorouracil and pelvic radiation in a phase III
intergroup trial (SWOG 9304). (Abstract #3640)
R. D. Ladner, C. M. Ulrich, C. J. Rankin, K. D. Danenberg, P. V. Danenberg,
S. R. Smalley, K. W. Makar, J. K. Benedetti, C. D. Blanke, H. Lenz
Brd. 15B Use of EGF a�61G and TS-5’UTR 2R/3R polymorphisms to predict complete
pathologic response in locally advanced rectal cancer patients undergoing
preoperative cetuximab-based chemoradiation followed by surgery.
(Abstract #3641)
S. Hu-Lieskovan, D. Yang, P. P. Grimminger, D. Arnold, K. Dellas, J. H. Machiels,
C. Roedel, V. Velenik, H. Lenz, D. Vallbohmer
Brd. 15C Predictors of site-specific recurrence following combined modality therapy
for locally advanced rectal cancer. (Abstract #3642)
P. Ding, D. Liska, K. A. Goodman, L. Saltz, J. G. Guillem, P. Paty, L. K. Temple,
G. M. Nash, W. D. Wong, M. R. Weiser
Brd. 15D Correlation of single nucleotide polymorphisms (SNPs) of hypoxia-related
genes with pathologic complete response (pCR) following neoadjuvant
chemoradiation (chemoXRT) for locally advanced rectal cancer.
(Abstract #3643)
M. Tanaka, I. Bedrosian, G. J. Chang, Y. N. You, P. Das, D. Li, M. A. Rodriguez-
Bigas, J. M. Skibber, J. L. Abbruzzese, C. Eng
264